USD 49.6 million
Report ID:
SQMIG35H2196 |
Region:
Global |
Published Date: January, 2025
Pages:
157
|Tables:
66
|Figures:
75
Global Bacteriophage Market size was valued at USD 49.6 million in 2023 and is poised to grow from USD 52.43 million in 2024 to USD 81.69 million by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).
The global bacteriophage market is gaining traction as a promising avenue for addressing antibiotic resistance and combating bacterial infections. Bacteriophages, or phages, are naturally occurring viruses that specifically target and infect bacteria, offering a potential alternative to traditional antibiotics. The market's growth is propelled by the rising concern over antibiotic-resistant bacteria, which pose a significant global health threat. Bacteriophages have garnered attention due to their high specificity, ability to evolve with bacteria, and minimal impact on beneficial microbiota. Phage therapy, the use of bacteriophages to treat bacterial infections, has shown promising results in preclinical and clinical studies. Research and development efforts are focused on identifying and isolating phages with therapeutic potential against various bacterial strains. Regulatory approvals for phage-based therapies have been granted in some regions, further bolstering market expansion. The market's future holds potential for growth as collaborations between pharmaceutical companies, research institutions, and regulatory bodies facilitate the development and commercialization of phage-based therapies. The ability of bacteriophages to target specific bacteria, reduce the risk of resistance, and offer personalized treatment options positions them as a valuable tool in the fight against antibiotic-resistant infections. Continued research, clinical trials, and regulatory advancements are expected to drive the Bacteriophage Market's evolution, making it a critical player in the global antimicrobial landscape.
US Bacteriophage Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2025-2032
Global Market Size
USD 49.6 million
Largest Segment
DsDNA Bacteriophage
Fastest Growth
DsDNA Bacteriophage
Growth Rate
5.7% CAGR
To get more reports on the above market click here to Buy The Report
Global Bacteriophage Market is segmented by Product Type, Route of Administration, Distribution Channel, Application, End-use Industry and region. Based on Product Type, the market is segmented into Phage Probiotics and Phage Therapeutics. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Application, the market is segmented into Gastroenterology, Respiratory Infections Treatment, Skin Infection Treatment, Wound Prophylaxis and Urological Infection Treatment. Based on End-use Industry, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
In the bacteriophage market, among the different types of bacteriophages, the DsDNA Bacteriophage segment holds a dominant position in the market. DsDNA (Double-stranded DNA) bacteriophages are widely studied and utilized due to their versatility and effectiveness in combating bacterial infections. Their ability to infect a broad range of bacterial species and their potential for various applications, including biocontrol agents, diagnostics, and research tools, contribute to their dominant market position.
On the other hand, the fastest-growing segment is the SsRNA Bacteriophage. Single-stranded RNA (SsRNA) bacteriophages have gained significant attention for their unique properties and potential applications. Their distinct mechanisms of action and potential in targeting specific bacteria offer novel avenues for bacterial control. As research advances and more applications are explored, the SsRNA Bacteriophage segment is projected to experience rapid growth, driven by its potential in precision medicine, biotechnology, and targeted therapies against bacterial infections. The increasing understanding of RNA-based technologies and the expanding scope of personalized medicine contribute to the rapid growth of this segment in the Bacteriophage Market.
In the Bacteriophage market, the dominant segment is likely to be Human Health. Bacteriophages, or phages, are viruses that specifically target and kill bacteria, making them a promising tool for combating bacterial infections, including antibiotic-resistant strains. The rising concern over antibiotic resistance has fueled research into alternative therapeutic options, boosting the use of bacteriophages for treating various bacterial infections in humans.
The fastest-growing segment is expected to be Agriculture. Bacteriophages are being explored as natural alternatives to chemical pesticides in agriculture. They can target harmful bacteria that cause plant diseases, offering a sustainable and environmentally friendly approach to crop protection. As the demand for safer and more sustainable agricultural practices increases, the adoption of bacteriophages in crop protection is likely to experience rapid growth, driving the Agriculture segment of the bacteriophage market.
To get detailed analysis on other segments, Request For Free Sample Report
The global bacteriophage market is analyzed based on its regional presence, which includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. In the Bacteriophage Market, North America stands out as a dominant region in terms of market share. The region's advanced healthcare infrastructure, robust research and development activities, and regulatory support for phage therapy contribute to its prominent position. Bacteriophages are gaining traction as potential alternatives to antibiotics, and North America's established pharmaceutical and biotechnology industry accelerates their integration into medical practices.
On the other hand, Asia-Pacific is experiencing the fastest growth in the bacteriophage market. Factors such as a high burden of antibiotic-resistant infections, increasing awareness about phage therapy, and growing investments in healthcare infrastructure are propelling the market forward in this region. Countries like India, China, and South Korea are witnessing rapid growth due to their large population, rising healthcare expenditures, and increasing demand for novel therapeutic options.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rise in Antibiotic Resistance:
Growing Focus on Personalized Medicine:
Regulatory Challenges:
Limited Clinical Data and Standardization:
Request Free Customization of this report to help us to meet your business objectives.
The global bacteriophage market's competitive landscape is evolving rapidly with a growing number of biotech companies focusing on phage-based therapies and solutions. Established players like Adaptive Phage Therapeutics, Pherecydes Pharma, and Eligo Bioscience lead in research and development. Collaborations between pharmaceutical giants and smaller startups are driving innovation and product pipelines. Regulatory approvals and clinical trials are shaping the market's dynamics, creating opportunities for new entrants. Intellectual property rights and technology acquisitions also influence the landscape. As the antimicrobial resistance crisis intensifies, the Bacteriophage market is expected to witness intensified competition, consolidation, and increased investment in research and commercialization efforts.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Component types team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global bacteriophage market analysis, the market is gaining momentum as a promising alternative to combat antibiotic-resistant bacterial infections. Bacteriophages are viruses that selectively infect and kill specific bacterial strains, offering a targeted and potentially more effective approach to treating infections. The rising global concern over antibiotic resistance, coupled with the need for novel therapeutic options, is driving market growth. Bacteriophages' ability to evolve and adapt to new strains of bacteria presents a dynamic solution in the fight against drug-resistant pathogens. However, challenges such as regulatory hurdles, limited clinical data, and manufacturing complexities need to be addressed. As research and clinical trials progress, and as the medical community seeks innovative treatments, the Bacteriophage Market is expected to expand. Continued investment in research, collaborations between academia and industry, and growing awareness of phage therapy's potential contribute to the market's optimistic outlook.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 49.6 million |
Market size value in 2032 | USD 81.69 million |
Growth Rate | 5.7% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Million |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Bacteriophage Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Bacteriophage Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Bacteriophage Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Bacteriophage Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
Bacteriophage Market was valued at USD 41.61 Million in 2023 and is poised to grow from USD 43.48 Million in 2024 to USD 61.83 Million by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).
The global bacteriophage market's competitive landscape is evolving rapidly with a growing number of biotech companies focusing on phage-based therapies and solutions. Established players like Adaptive Phage Therapeutics, Pherecydes Pharma, and Eligo Bioscience lead in research and development. Collaborations between pharmaceutical giants and smaller startups are driving innovation and product pipelines. Regulatory approvals and clinical trials are shaping the market's dynamics, creating opportunities for new entrants. Intellectual property rights and technology acquisitions also influence the landscape. As the antimicrobial resistance crisis intensifies, the Bacteriophage market is expected to witness intensified competition, consolidation, and increased investment in research and commercialization efforts. 'Microgen (U.S.)', 'Micreos (Netherlands)', 'ATCC (U.S.)', 'Intralytix, Inc. (U.S.)', 'Adaptive Phage Therapeutics (U.S.)', 'Armata pharmaceuticals Inc. (U.S.)', 'LOCUS BIOSCIENCES, INC. (U.S.)', 'Delmont Laboratories, Inc. (U.S.)', 'Nextbiotics (U.S.)', 'Pherecydes Pharma (France)', 'iNtODEWORLD. Inc. (U.S.)', 'Enbiotix (U.S.)', 'Fixed-Phage Limited (U.K.)', 'Cytophage Technologies Inc. (Canada)', 'Eliava Bio Preparations LTD (Georgia)', 'Phagelux, Inc. (China)', 'InnoPhage, Ltd (Hong Kong)', 'TechnoPhage (Portugal)', 'Eligo Bioscience SA (France)', 'BiomX Ltd. (Israel)'
The increasing prevalence of antibiotic-resistant bacterial infections has driven the demand for alternative treatment options. Bacteriophages, which are viruses that target and kill specific bacteria, offer a promising avenue for combating antibiotic-resistant bacteria and superbugs. As conventional antibiotics become less effective, the bacteriophage market is propelled by the need for innovative and personalized therapeutic approaches.
Rising Interest in Phage Therapy: There is a growing interest in the use of bacteriophages (viruses that infect and kill bacteria) for therapeutic purposes, known as phage therapy. As antibiotic resistance becomes a critical global health concern, researchers and healthcare professionals are exploring alternative treatments. Bacteriophages have shown potential in targeting specific bacterial infections, especially those resistant to antibiotics. The increasing understanding of phage biology, advances in phage isolation and production, and successful case studies are driving the exploration of phage therapy as a viable medical intervention.
The global bacteriophage market is analyzed based on its regional presence, which includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. In the Bacteriophage Market, North America stands out as a dominant region in terms of market share. The region's advanced healthcare infrastructure, robust research and development activities, and regulatory support for phage therapy contribute to its prominent position. Bacteriophages are gaining traction as potential alternatives to antibiotics, and North America's established pharmaceutical and biotechnology industry accelerates their integration into medical practices.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35H2196
[email protected]
USA +1 351-333-4748